Thomas NystrÃ¶m

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4053607/publications.pdf

Version: 2024-02-01

90	3,860	147801	128289
papers	citations	31 h-index	60 g-index

92	92	92	5147
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Evaluation of Effects of Continuous Glucose Monitoring on Physical Activity Habits and Blood Lipid Levels in Persons With Type 1 Diabetes Managed With Multiple Daily Insulin Injections: An Analysis Based on the GOLD Randomized Trial (GOLD 8). Journal of Diabetes Science and Technology, 2024, 18, 89-98.	2.2	2
2	A High-Fat Diet Increases Activation of the Glucagon-Like Peptide-1-Producing Neurons in the Nucleus Tractus Solitarii: an Effect that is Partially Reversed by Drugs Normalizing Glycemia. Cellular and Molecular Neurobiology, 2022, 42, 1995-2002.	3.3	2
3	Normalisation of glucose metabolism by exendinâ€4 in the chronic phase after stroke promotes functional recovery in male diabetic mice. British Journal of Pharmacology, 2022, 179, 677-694.	5.4	12
4	Risk factors for nephropathy in persons with type 1 diabetes: a population-based study. Acta Diabetologica, 2022, , 1.	2.5	3
5	LDL cholesterol level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes mellitus: A nationwide cohort study. Journal of Internal Medicine, 2021, 289, 873-886.	6.0	10
6	The majority of people with type <scp>1</scp> diabetes and multiple daily insulin injections benefit from using continuous glucose monitoring: An analysis based on the <scp>GOLD</scp> randomized trial (<scp>GOLDâ€5</scp>). Diabetes, Obesity and Metabolism, 2021, 23, 619-630.	4.4	9
7	Cardiovascular and Renal Disease Burden in Type 1 Compared With Type 2 Diabetes: A Two-Country Nationwide Observational Study. Diabetes Care, 2021, 44, 1211-1218.	8.6	32
8	Early and long-term prognosis in patients with and without type 2 diabetes after carotid intervention: a Swedish nationwide propensity score matched cohort study. Cardiovascular Diabetology, 2021, 20, 85.	6.8	2
9	Risk of stent failure in patients with diabetes treated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors: A nationwide observational study. International Journal of Cardiology, 2021, 330, 23-29.	1.7	6
10	Development of type 2 diabetes and insulin resistance in people with HIV infection: Prevalence, incidence and associated factors. PLoS ONE, 2021, 16, e0254079.	2.5	6
11	The Stroke-Induced Increase of Somatostatin-Expressing Neurons is Inhibited by Diabetes: A Potential Mechanism at the Basis of Impaired Stroke Recovery. Cellular and Molecular Neurobiology, 2021, 41, 591-603.	3.3	5
12	Reduced expression of OXPHOS and DNA damage genes is linked to protection from microvascular complications in long-term type 1 diabetes: the PROLONG study. Scientific Reports, 2021, 11, 20735.	3.3	7
13	Estimated glucose disposal rate and risk of stroke and mortality in type 2 diabetes: a nationwide cohort study. Cardiovascular Diabetology, 2021, 20, 202.	6.8	19
14	Diet-induced weight loss in obese/diabetic mice normalizes glucose metabolism and promotes functional recovery after stroke. Cardiovascular Diabetology, 2021, 20, 240.	6.8	5
15	Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride. Cardiovascular Diabetology, 2021, 20, 237.	6.8	14
16	Risk of first stroke in people with type 2 diabetes and its relation to glycaemic control: A nationwide observational study. Diabetes, Obesity and Metabolism, 2020, 22, 182-190.	4.4	24
17	Liver nucleotide biosynthesis is linked to protection from vascular complications in individuals with long-term type 1 diabetes. Scientific Reports, 2020, 10, 11561.	3.3	8
18	Increased Plasma Soluble Interleukin-2 Receptor Alpha Levels in Patients With Long-Term Type 1 Diabetes With Vascular Complications Associated With IL2RA and PTPN2 Gene Polymorphisms. Frontiers in Endocrinology, 2020, 11, 575469.	3.5	4

#	Article	IF	Citations
19	Western Diet Accelerates the Impairment of Odor-Related Learning and Olfactory Memory in the Mouse. ACS Chemical Neuroscience, 2020, 11, 3590-3602.	3.5	14
20	Regulation of Glycemia in the Recovery Phase After Stroke Counteracts the Detrimental Effect of Obesity-Induced Type 2 Diabetes on Neurological Recovery. Diabetes, 2020, 69, 1961-1973.	0.6	16
21	Heart failure is a common complication after acute myocardial infarction in patients with diabetes: A nationwide study in the SWEDEHEART registry. European Journal of Preventive Cardiology, 2020, 27, 1890-1901.	1.8	24
22	Dipeptidyl peptidase-4 inhibitors and sulfonylureas prevent the progressive impairment of the nigrostriatal dopaminergic system induced by diabetes during aging. Neurobiology of Aging, 2020, 89, 12-23.	3.1	13
23	Dapagliflozin vs nonâ€SGLTâ€2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLAREâ€TIMI 58 trial: A nationwide observational study. Diabetes, Obesity and Metabolism, 2019, 21, 2651-2659.	4.4	10
24	Obesity-induced type 2 diabetes impairs neurological recovery after stroke in correlation with decreased neurogenesis and persistent atrophy of parvalbumin-positive interneurons. Clinical Science, 2019, 133, 1367-1386.	4.3	21
25	Oxygen Therapy in Myocardial Infarction Patients With or Without Diabetes: A Predefined Subgroup Analysis From the DETO2X-AMI Trial. Diabetes Care, 2019, 42, 2032-2041.	8.6	7
26	Dipeptidyl Peptidase-4 Inhibitors for the Potential Treatment of Brain Disorders; A Mini-Review With Special Focus on Linagliptin and Stroke. Frontiers in Neurology, 2019, 10, 493.	2.4	15
27	Excess risk of lower extremity amputations in people with type 1 diabetes compared with the general population: amputations and type 1 diabetes. BMJ Open Diabetes Research and Care, 2019, 7, e000602.	2.8	17
28	Glycated Hemoglobin A1c Levels in Type 1 Diabetes Mellitus and Outcomes After Myocardial Infarction. Circulation, 2019, 139, 2380-2382.	1.6	2
29	Heart rate variability in type 2 diabetic subjects randomized to liraglutide or glimepiride treatment, both in combination with metformin: A randomized, open, parallelâ€group study. Endocrinology, Diabetes and Metabolism, 2019, 2, e00058.	2.4	8
30	P6400Risk for heart failure after acute myocardial infarction, a nationwide report on 73 303 patients with and without diabetes 2012â€“2017 in the SWEDEHEART-SCAAR registry. European Heart Journal, 2019, 40, .	2.2	0
31	Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLAREâ€TIMI 58 trial: A nationwide observational study. Diabetes, Obesity and Metabolism, 2019, 21, 1136-1145.	4.4	61
32	A Randomized Clinical Trial of the Effect of Continuous Glucose Monitoring on Nocturnal Hypoglycemia, Daytime Hypoglycemia, Glycemic Variability, and Hypoglycemia Confidence in Persons with Type 1 Diabetes Treated with Multiple Daily Insulin Injections (GOLD-3). Diabetes Technology and Therapeutics, 2018, 20, 274-284.	4.4	88
33	Effects on repetitive 24-hour ambulatory blood pressure in subjects with type II diabetes randomized to liraglutide or glimepiride treatment both in combination with metformin: a randomized open parallel-group study. Journal of the American Society of Hypertension, 2018, 12, 346-355.	2.3	5
34	Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin. Acta Neuropathologica Communications, 2018, 6, 14.	5.2	37
35	Glucagon-like receptor 1 agonists and DPP-4 inhibitors: Anti-diabetic drugs with anti-stroke potential. Neuropharmacology, 2018, 136, 280-286.	4.1	30
36	Estimated glucose disposal rate predicts mortality in adults with type 1 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 556-563.	4.4	58

#	Article	IF	Citations
37	Dapagliflozin is associated with lower risk of cardiovascular events and allâ€cause mortality in people with type 2 diabetes (<scp>CVDâ€REAL Nordic</scp>) when compared with dipeptidyl peptidaseâ€4 inhibitor therapy: <scp>A</scp> multinational observational study. Diabetes, Obesity and Metabolism, 2018, 20, 344-351.	4.4	164
38	Different patterns of secondâ€line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study. Endocrinology, Diabetes and Metabolism, 2018, 1, e00036.	2.4	24
39	Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6â€“10. Diabetes Care, 2018, 41, e104-e105.	8.6	5
40	The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1Î±/CXCR4 pathway. Cardiovascular Diabetology, 2018, 17, 60.	6.8	46
41	Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006â€“2014. PharmacoEconomics - Open, 2018, 2, 393-402.	1.8	14
42	Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections. JAMA - Journal of the American Medical Association, 2017, 317, 379.	7.4	520
43	Novel oral glucoseâ€lowering drugs are associated with lower risk of allâ€cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 831-841.	4.4	75
44	Type 2 diabetes alters hippocampal gamma oscillations: A potential mechanism behind impaired cognition. Psychoneuroendocrinology, 2017, 82, 46-50.	2.7	10
45	Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia. Diabetes Research and Clinical Practice, 2017, 123, 199-208.	2.8	44
46	Dapagliflozin Is Associated With Lower Risk Of Hospitalization For Kidney Disease, Heart Failure And All Cause Death Compared To DPP-4i: CVD-REAL Nordic. Canadian Journal of Diabetes, 2017, 41, S51.	0.8	1
47	PCI Versus CABG in Patients With TypeÂ1ÂDiabetesÂand Multivessel Disease. Journal of the American College of Cardiology, 2017, 70, 1441-1451.	2.8	21
48	Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes and Endocrinology,the, 2017, 5, 709-717.	11.4	285
49	Estimated glucose disposal rate and long-term survival in type 2 diabetes after coronary artery bypass grafting. Heart and Vessels, 2017, 32, 269-278.	1.2	15
50	Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment vs. Glimepiride Both in Combination with Metformin: A Randomized Open Parallel-Group Study. Frontiers in Endocrinology, 2017, 8, 325.	3.5	17
51	Diabetes negatively affects cortical and striatal GABAergic neurons: an effect that is partially counteracted by exendin-4. Bioscience Reports, 2016, 36, .	2.4	20
52	Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006â€“2013. Diabetologia, 2016, 59, 1692-1701.	6.3	93
53	Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality. Diabetes Research and Clinical Practice, 2016, 117, 39-47.	2.8	68
54	Gliptinâ€mediated neuroprotection against stroke requires chronic pretreatment and is independent of glucagonâ€like peptideâ€1 receptor. Diabetes, Obesity and Metabolism, 2016, 18, 537-541.	4.4	37

#	Article	IF	Citations
55	Exenatide infusion decreases atrial natriuretic peptide levels by reducing cardiac filling pressures in type 2 diabetes patients with decompensated congestive heart failure. Diabetology and Metabolic Syndrome, 2016, 8, 5.	2.7	14
56	Earlier intensified insulin treatment of Type 1 diabetes and its association with longâ€term macrovascular and renal complications. Diabetic Medicine, 2016, 33, 463-470.	2.3	2
57	Relationship between preoperative hemoglobin A1c levels and long-term mortality after coronary artery bypass grafting in patients with type 2 diabetes mellitus. International Journal of Cardiology, 2016, 202, 291-296.	1.7	33
58	Role of Prolactin Receptors in Lymphangioleiomyomatosis. PLoS ONE, 2016, 11, e0146653.	2.5	8
59	Pituitary Adenlylate Cyclase Activating Peptide Protects Adult Neural Stem Cells from a Hypoglycaemic milieu. PLoS ONE, 2016, 11, e0156867.	2.5	8
60	Stimulation of prolactin receptor induces STAT-5 phosphorylation and cellular invasion in glioblastoma multiforme. Oncotarget, 2016, 7, 79572-79583.	1.8	14
61	Type 2 diabetes-induced neuronal pathology in the piriform cortex of the rat is reversed by the GLP-1 receptor agonist exendin-4. Oncotarget, 2016, 7, 5865-5876.	1.8	23
62	Antidiabetic Agents and Endothelial Dysfunction â€“ Beyond Glucose Control. Basic and Clinical Pharmacology and Toxicology, 2015, 117, 15-25.	2.5	40
63	Longâ€Term Risk of Stroke in Patients With Type 1 and Type 2 Diabetes Following Coronary Artery Bypass Grafting. Journal of the American Heart Association, 2015, 4, .	3.7	9
64	Circadian hormone profiles and insulin sensitivity in patients with Addison's disease: a comparison of continuous subcutaneous hydrocortisone infusion with conventional glucocorticoid replacement therapy. Clinical Endocrinology, 2015, 83, 28-35.	2.4	34
65	Glucagon-Like Receptor 1 Agonists and DPP-4 Inhibitors: Potential Therapies for the Treatment of Stroke. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 718-723.	4.3	35
66	Glycemic Control in Type 1 Diabetes andÂLong-Term Risk of Cardiovascular Events or Death After Coronary ArteryÂBypass Grafting. Journal of the American College of Cardiology, 2015, 66, 535-543.	2.8	39
67	Long-Term Prognosis in Patients With Type 1 and 2 Diabetes Mellitus After Coronary Artery Bypass Grafting. Journal of the American College of Cardiology, 2015, 65, 1644-1652.	2.8	58
68	Abstract 476: Glucagon Like Peptide -1 Receptor Activation Does Not Affect Re-endothelialization But Reduces Intimal Hyperplasia via Direct Effects on Smooth Muscle Cells in a Non-diabetic Model of Arterial Injury. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, .	2.4	0
69	Abstract 17564: Long-term Risk of Stroke in Patients With Type 1 and Type 2 Diabetes Following Coronary Artery Bypass Grafting. Circulation, 2015, 132, .	1.6	0
70	Activation of AMP-activated protein kinase by metformin protects human coronary artery endothelial cells against diabetic lipoapoptosis. Cardiovascular Diabetology, 2014, 13, 152.	6.8	37
71	Sex, Diastolic Blood Pressure, and Outcome after Thrombolysis for Ischemic Stroke. Stroke Research and Treatment, 2014, 2014, 1-7.	0.8	8
72	Insulin sensitivity and beta-cell function after carbohydrate oral loading in hip replacement surgery: A double-blind, randomised controlled clinical trial. Clinical Nutrition, 2014, 33, 392-398.	5.0	33

#	Article	IF	Citations
73	Effects of high-fat diet and the anti-diabetic drug metformin on circulating GLP-1 and the relative number of intestinal L-cells. Diabetology and Metabolic Syndrome, 2014, 6, 70.	2.7	35
74	Intensified insulin treatment is associated with improvement in skin microcirculation and ischaemic foot ulcer in patients with type 1 diabetes mellitus: a long-term follow-up study. Diabetologia, 2014, 57, 1703-1710.	6.3	21
75	Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice. Regulatory Peptides, 2014, 190-191, 25-31.	1.9	23
76	Exendin-4 Reduces Ischemic Brain Injury in Normal and Aged Type 2 Diabetic Mice and Promotes Microglial M2 Polarization. PLoS ONE, 2014, 9, e103114.	2.5	80
77	Abstract 515: Effects of the Glucagon-Like Peptide-1 Analog Exendin-4 on Reendothelialization and Intimal Hyperplasia Formation in an Animal Model of Vascular Injury. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, .	2.4	0
78	Exendin-4 protects endothelial cells from lipoapoptosis by PKA, PI3K, eNOS, p38 MAPK, and JNK pathways. Journal of Molecular Endocrinology, 2013, 50, 229-241.	2.5	58
79	Inorganic nitrite stimulates pancreatic islet blood flow and insulin secretion. Free Radical Biology and Medicine, 2012, 53, 1017-1023.	2.9	74
80	Effects of some anti-diabetic and cardioprotective agents on proliferation and apoptosis of human coronary artery endothelial cells. Cardiovascular Diabetology, 2012, 11, 27.	6.8	18
81	Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. Diabetologia, 2012, 55, 926-935.	6.3	87
82	Hypoglycemic pharmacological treatment of type 2 diabetes: Targeting the endothelium. Molecular and Cellular Endocrinology, 2009, 297, 112-126.	3.2	40
83	The Potential Beneficial Role of Glucagon-like Peptide-1 in Endothelial Dysfunction and Heart Failure Associated with Insulin Resistance. Hormone and Metabolic Research, 2008, 40, 593-606.	1.5	64
84	C-reactive protein: a marker or a player?. Clinical Science, 2007, 113, 79-81.	4.3	26
85	Increased levels of tumour necrosis factor-Î± (TNF-Î±) in patients with Type II diabetes mellitus after myocardial infarction are related to endothelial dysfunction. Clinical Science, 2006, 110, 673-681.	4.3	43
86	Persistent endothelial dysfunction is related to elevated C-reactive protein (CRP) levels in Type II diabetic patients after acute myocardial infarction. Clinical Science, 2005, 108, 121-128.	4.3	26
87	Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regulatory Peptides, 2005, 125, 173-177.	1.9	161
88	Tetrahydrobiopterin increases insulin sensitivity in patients with type 2 diabetes and coronary heart disease. American Journal of Physiology - Endocrinology and Metabolism, 2004, 287, E919-E925.	3.5	56
89	Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. American Journal of Physiology - Endocrinology and Metabolism, 2004, 287, E1209-E1215.	3.5	583
90	Bezafibrate-induced improvement in glucose uptake and endothelial function in protease inhibitor-associated insulin resistance. Journal of Internal Medicine, 2002, 252, 570-574.	6.0	14